Abstract
The aim: To determine the prognostic value of endothelial monocytic peptide ІІ in the course of AMI (acute myocardial infarction) in combination with type 2 diabetes mellitus (DM) Materials and methods: The study involved 120 patients divided in 2 groups: Group 1 – patients with acute myocardial infarction (AMI) with concomitant type 2 DM (n=69); Group 2 – patients with AMI without concomitant type 2 DM (n=51). Control group was composed with 20 almost healthy persons. Results: It was determined that in patients with AMI in combination with type 2 diabetes, the level of endothelial monocyte-activating polypeptide II (EMAP-II) was 1.65 times higher than in patients without concomitant type 2 DM (p <0.05). The patients with AMI and type 2 DM who were included in the group of the 3rd tertile according to level of EMAR-II had the complicated course compared to patients in the groups of the 1st and 2nd tertiles. Q-positive AMI was found in 100% of patients who belonged to the group of the 3rd tertile; recurrence of AMI occurred only in patients whose EMAR-II index was included in the 3rd tertile. Conclusions: According to the results of endothelial function analysis with usу ща the marker of EMAP-II endothelial dysfunction in patients with AMI and concomitant type 2 DM, the increased level of this parameter was characteristic of pronounced violation of dilatation properties of the vascular wall and of the other indicators of complicated comorbid conditions.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.